Whole-genome sequencing in cancer treatment (WGS) is increasingly recognized for its potential by providing detailed biological information about tumors. National initiatives in countries like England, Australia, and Sweden have started incorporating WGS for certain cancer patients. However, the impact on long-term patient outcomes of whole-genome sequencing in cancer treatment remains largely unstudied. A study in England, published on July 2, 2024, evaluated WGS in routine care for children with cancer, finding that WGS provided additional clinical information for 29% of patients and led to treatment changes for 7%. A similar study on sarcoma patients showed treatment plan changes for 33% of patients, but no alterations for 67%. These findings suggest that while whole-genome sequencing in cancer treatment can be routinely implemented and offer benefits in personalized care, it does not impact treatment decisions for the majority of patients. Therefore, further investigation into the cost-effectiveness of WGS is necessary before it can be widely adopted.1
Continue reading here.
References
- Editorial. (2024). Incorporating whole-genome sequencing into cancer care. The Lancet Oncology, 25, 945. https://www.thelancet.com/action/showPdf?pii=S1470-2045%2824%2900401-7
Disclaimers
- The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
- Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
- No official support by any organization(s) has been provided or should be inferred
